JP2001521386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001521386A5 JP2001521386A5 JP1998543387A JP54338798A JP2001521386A5 JP 2001521386 A5 JP2001521386 A5 JP 2001521386A5 JP 1998543387 A JP1998543387 A JP 1998543387A JP 54338798 A JP54338798 A JP 54338798A JP 2001521386 A5 JP2001521386 A5 JP 2001521386A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK41897 | 1997-04-15 | ||
| US4418797P | 1997-04-24 | 1997-04-24 | |
| US60/044,187 | 1997-04-24 | ||
| US0418/97 | 1997-04-24 | ||
| PCT/DK1998/000157 WO1998046642A1 (en) | 1997-04-15 | 1998-04-15 | MODIFIED TNFα MOLECULES, DNA ENCODING SUCH MODIFIED TNFα MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFα MOLECULES AND DNA |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001521386A JP2001521386A (ja) | 2001-11-06 |
| JP2001521386A5 true JP2001521386A5 (OSRAM) | 2005-11-24 |
Family
ID=8093298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54338798A Pending JP2001521386A (ja) | 1997-04-15 | 1998-04-15 | 被修飾ＴＮＦα分子、このような被修飾ＴＮＦα分子をコードするＤＮＡ、並びにこのような被修飾ＴＮＦα分子及びＤＮＡを具備するワクチン |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US7118750B1 (OSRAM) |
| EP (1) | EP0975668B1 (OSRAM) |
| JP (1) | JP2001521386A (OSRAM) |
| KR (1) | KR100522289B1 (OSRAM) |
| CN (1) | CN1178955C (OSRAM) |
| AR (1) | AR012427A1 (OSRAM) |
| AT (1) | ATE326481T1 (OSRAM) |
| AU (1) | AU743400B2 (OSRAM) |
| BR (1) | BR9811462A (OSRAM) |
| CA (1) | CA2289476A1 (OSRAM) |
| CZ (1) | CZ9903657A3 (OSRAM) |
| DE (1) | DE69834556T2 (OSRAM) |
| DK (1) | DK0975668T3 (OSRAM) |
| EE (1) | EE9900461A (OSRAM) |
| ES (1) | ES2264569T3 (OSRAM) |
| HR (1) | HRP980203B1 (OSRAM) |
| HU (1) | HUP0001930A3 (OSRAM) |
| IL (1) | IL132281A0 (OSRAM) |
| NO (1) | NO995002L (OSRAM) |
| NZ (1) | NZ337955A (OSRAM) |
| PL (1) | PL194221B1 (OSRAM) |
| RU (1) | RU2241715C2 (OSRAM) |
| SI (1) | SI0975668T1 (OSRAM) |
| SK (1) | SK285639B6 (OSRAM) |
| TR (1) | TR199902562T2 (OSRAM) |
| TW (1) | TW510921B (OSRAM) |
| UA (1) | UA72440C2 (OSRAM) |
| WO (1) | WO1998046642A1 (OSRAM) |
| ZA (1) | ZA983148B (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
| WO2000051637A1 (en) * | 1999-03-02 | 2000-09-08 | Centocor, Inc. | ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| WO2000067777A1 (en) * | 1999-05-07 | 2000-11-16 | Biofan Pty Ltd | A method of prophylaxis and treatment and agents useful therefor |
| SK722002A3 (en) | 1999-07-20 | 2003-02-04 | Pharmexa As | Method for down-regulating GDF-8 activity |
| WO2001097837A1 (en) * | 2000-06-21 | 2001-12-27 | Ferring Bv | Solubilised protein vaccines |
| WO2003075951A2 (en) * | 2002-03-11 | 2003-09-18 | Pharmexa A/S | Novel application of vaccination against tnf-alpha |
| FR2844514B1 (fr) * | 2002-09-16 | 2007-10-19 | Neovacs | Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| MXPA05008156A (es) * | 2003-02-01 | 2005-09-30 | Neuralab Ltd | Inmunizacion activa para generar anticuerpos para beta-a soluble. |
| MXPA06009805A (es) | 2004-02-27 | 2007-04-02 | Vaxconsulting | Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos. |
| PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
| KR101465456B1 (ko) | 2005-05-16 | 2014-11-27 | 애브비 바이오테크놀로지 리미티드 | 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도 |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| KR20100084623A (ko) * | 2007-09-25 | 2010-07-27 | 인터벳 인터내셔널 비.브이. | 골관절염 치료용 백신 |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| WO2011057099A2 (en) | 2009-11-05 | 2011-05-12 | The Uab Research Foundation | Treating basal-like genotype cancers |
| US8703712B2 (en) | 2010-03-18 | 2014-04-22 | The Uab Research Foundation | Targeting cancer stem cells with DR5 agonists |
| US8907053B2 (en) * | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| EP2462950A1 (en) | 2010-12-08 | 2012-06-13 | Neovacs | Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof |
| CA2820837A1 (en) | 2010-12-08 | 2012-06-14 | Neovacs | Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof |
| CN102539778A (zh) * | 2010-12-24 | 2012-07-04 | 北京义翘神州生物技术有限公司 | 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒 |
| JP2011201902A (ja) * | 2011-05-19 | 2011-10-13 | Wyeth Llc | 可溶性Ａ−βに対する抗体を生成させるための能動免疫 |
| CN103376327A (zh) * | 2012-04-28 | 2013-10-30 | 通用电气公司 | 检测抗体或融合蛋白的浓度的方法 |
| AU2016256876B2 (en) | 2015-05-05 | 2021-02-04 | Rubicon Biotechnology Llc | Cancer immunotherapeutic |
| CN106279403B (zh) * | 2016-08-16 | 2019-06-11 | 长春市海兰深生物医学技术有限公司 | 一种检测天然肺癌相关抗体的组合物、试剂盒和方法 |
| CN106478802B (zh) * | 2016-10-11 | 2019-08-09 | 浙江省人民医院 | TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3750056T2 (de) | 1986-06-20 | 1995-04-06 | Dainippon Pharmaceutical Co | Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS. |
| DE3843534A1 (de) * | 1988-12-23 | 1990-07-12 | Basf Ag | Neue tnf-polypeptide |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| AU634379B2 (en) | 1991-04-29 | 1993-02-18 | Csl Limited | Recombinant immunocastration vaccine |
| SE9102808L (sv) * | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| CA2119089A1 (en) | 1993-03-29 | 1994-09-30 | David Banner | Tumor necrosis factor muteins |
| DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
-
1998
- 1998-04-15 IL IL13228198A patent/IL132281A0/xx unknown
- 1998-04-15 PL PL98336295A patent/PL194221B1/pl not_active IP Right Cessation
- 1998-04-15 US US09/060,294 patent/US7118750B1/en not_active Expired - Fee Related
- 1998-04-15 EP EP98916866A patent/EP0975668B1/en not_active Expired - Lifetime
- 1998-04-15 AU AU70303/98A patent/AU743400B2/en not_active Ceased
- 1998-04-15 AT AT98916866T patent/ATE326481T1/de not_active IP Right Cessation
- 1998-04-15 RU RU99122686/13A patent/RU2241715C2/ru not_active IP Right Cessation
- 1998-04-15 TR TR1999/02562T patent/TR199902562T2/xx unknown
- 1998-04-15 HU HU0001930A patent/HUP0001930A3/hu unknown
- 1998-04-15 ES ES98916866T patent/ES2264569T3/es not_active Expired - Lifetime
- 1998-04-15 BR BR9811462-0A patent/BR9811462A/pt not_active Application Discontinuation
- 1998-04-15 DE DE69834556T patent/DE69834556T2/de not_active Expired - Fee Related
- 1998-04-15 EE EEP199900461A patent/EE9900461A/xx unknown
- 1998-04-15 ZA ZA9803148A patent/ZA983148B/xx unknown
- 1998-04-15 SK SK1409-99A patent/SK285639B6/sk unknown
- 1998-04-15 CN CNB988042142A patent/CN1178955C/zh not_active Expired - Fee Related
- 1998-04-15 HR HR980203A patent/HRP980203B1/xx not_active IP Right Cessation
- 1998-04-15 UA UA99116210A patent/UA72440C2/uk unknown
- 1998-04-15 WO PCT/DK1998/000157 patent/WO1998046642A1/en not_active Ceased
- 1998-04-15 KR KR10-1999-7009504A patent/KR100522289B1/ko not_active Expired - Fee Related
- 1998-04-15 SI SI9830845T patent/SI0975668T1/sl unknown
- 1998-04-15 JP JP54338798A patent/JP2001521386A/ja active Pending
- 1998-04-15 NZ NZ337955A patent/NZ337955A/xx unknown
- 1998-04-15 DK DK98916866T patent/DK0975668T3/da active
- 1998-04-15 CA CA002289476A patent/CA2289476A1/en not_active Abandoned
- 1998-04-15 AR ARP980101722A patent/AR012427A1/es unknown
- 1998-04-15 CZ CZ19993657A patent/CZ9903657A3/cs unknown
- 1998-07-20 TW TW087111808A patent/TW510921B/zh not_active IP Right Cessation
-
1999
- 1999-10-14 NO NO995002A patent/NO995002L/no not_active Application Discontinuation